Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
ENGN
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
Earnings Growth
YoY
Current
Estimates
Q3.23
N/A
-0.30
vs -0.43
Q4.23
N/A
-2.64
vs -0.53
Q1.24
N/A
-0.46
vs -0.47
Q2.24
N/A
-0.38
vs -0.33
Q3.24
N/A
-0.32
vs -0.30
Q4.24
N/A
-0.34
vs -2.64
Q1.25
N/A
-0.48
vs -0.46
Q2.25
+100%
NA
vs -0.38
Q3.25
N/A
-0.50
vs -0.32
Q4.25
N/A
-0.52
vs -0.34
Sales Growth
YoY
Current
Estimates
Q1.23
NA
NA vs NA
Q2.23
NA
NA vs NA
Q3.23
NA
NA vs NA
Q4.23
NA
NA vs NA
Q1.24
NA
NA vs NA
Q2.24
NA
NA vs NA
Q3.24
NA
NA vs NA
Q4.24
NA
NA vs NA
Q1.25
NA
NA vs NA
Q2.25
NA
NA vs NA
Return on Equity
QoQ
Q3.23
+5%
0.05
vs 0.06
Q4.23
-114%
-1.14
vs 0.05
Q1.24
-17%
-0.17
vs -1.14
Q2.24
-6%
-0.06
vs -0.17
Q3.24
-6%
-0.06
vs -0.06
Q4.24
-6%
-0.06
vs -0.06
Q1.25
-10%
-0.10
vs -0.06
Q2.25
+11%
0.11
vs -0.10
Institutionnal Ownership
QoQ
Q4.23
11
11
vs NA
NA
Q1.24
31
31
vs 11
182%
Q2.24
30
30
vs 31
-3%
Q3.24
30
30
vs 30
NA
Q4.24
34
34
vs 30
13%
Q1.25
31
31
vs 34
-9%
businesswire.com
8 hours ago
businesswire.com
8 hours ago
businesswire.com
8 hours ago
businesswire.com
8 hours ago
seekingalpha.com
16 hours ago
enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.
NASDAQ
Unprofitable
EPS improving
Unprofitable
EPS improving
-0.02 ( -0.55%)
Relative Strenght
5
Volume Buzz
-13%
Earning Acce
No
Dist 52w H.
67%Relative Strength
ENGN
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
NaN%2026-Revenue
-536%2026-EPS
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Buy
Price Target
0.00(-100.00%)
Number of analyst
0
Last analyst upgrade/downgrade
JMP Securities
initialisePrevious: Not converted
2024-11-18
Now: Market Outperform
Oppenheimer
initialisePrevious: Not converted
2024-08-27
Now: Outperform
Guggenheim
initialisePrevious: Not converted
2024-04-15
Now: Buy
UBS
initialisePrevious: Not converted
2024-03-28
Now: Buy
Fundamentals
P/E Ratio
P/S Ratio
P/B Ratio
Debt/Equity
Net Margin
EPS
How ENGN compares to sector?
ENGN
-7x